NC
PDSB icon

Nexthera Capital’s PDS Biotechnology PDSB Stock Holding History

Nexthera Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,792
Closed -$1.37M – 36
2016
Q2 		$1.37M Buy
+6,792
New +$1.2M 1.19% 17

Other funds holding PDSB

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Nexthera Capital's PDSB Position: Q3 2016 in Review

Nexthera Capital sold out of PDS Biotechnology (PDSB) in Q3 2016, closing a stake of 6,792 shares — an estimated $1.37M sold.

Nexthera Capital first reported a position in PDSB in Q2 2016 and held it in 1 quarter. The position peaked at $1.37M in Q2 2016. 51 funds tracked by Wall St. Rank hold PDSB as of Q3 2016.

  • Nexthera Capital reported no remaining PDS Biotechnology position as of Q3 2016 after selling out during the quarter.
  • Nexthera Capital sold 6,792 PDS Biotechnology shares in Q3 2016, an estimated $1.37M.
  • Nexthera Capital first reported a position in PDS Biotechnology in Q2 2016 and held it in 1 quarter.
  • Nexthera Capital's PDS Biotechnology position peaked at $1.37M in Q2 2016.
  • 51 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2016.

Based on Nexthera Capital's 13F filing for Q3 2016, filed 14 Nov 2016.